Novavax, Inc. (NASDAQ:NVAX) has received a consensus rating of “Hold” from the twelve brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $36.00.
A number of equities research analysts recently issued reports on NVAX shares. Oppenheimer lifted their target price on Novavax from $1.25 to $25.00 in a research report on Monday, May 13th. Zacks Investment Research raised Novavax from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Thursday, May 16th. Chardan Capital reissued a “neutral” rating and issued a $7.00 target price on shares of Novavax in a research report on Friday, May 10th. HC Wainwright lifted their target price on Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, ValuEngine raised Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
Several large investors have recently bought and sold shares of NVAX. Legal & General Group Plc boosted its position in shares of Novavax by 30.9% in the fourth quarter. Legal & General Group Plc now owns 74,389 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 17,575 shares during the period. Wedbush Securities Inc. boosted its position in shares of Novavax by 102.1% in the first quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 27,500 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of Novavax in the first quarter valued at approximately $40,000. Creative Planning boosted its position in shares of Novavax by 161.7% in the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 317,204 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Novavax by 7,685.2% in the first quarter. BNP Paribas Arbitrage SA now owns 79,331 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 78,312 shares during the period.
Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million during the quarter, compared to analyst estimates of $3.53 million. During the same quarter in the previous year, the company posted ($2.40) earnings per share. Equities analysts forecast that Novavax will post -5.6 EPS for the current year.
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Featured Story: Federal Reserve
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.